Pharmaceutical Contract Manufacturing: Current Market Landscape and Future Opportunities
The present pipeline of pharmaceutical products is becoming increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. Over the years, the contract manufacturing market has grown into a prominent and promising segment of the overall pharmaceutical industry. In fact, post 2000, more than 150 new CMOs have been established, offering cost-efficient solutions to several stakeholders in the industry.
Sample Insight 1
Discussions with several industry stakeholders not only confirm the present importance of CMOs but also highlight the value likely to be created by them in the long term
Sample Insight 2
The contract services market landscape, featuring the presence of over 500 companies, is highly fragmented; a number of players have both API and FDF manufacturing capability
Sample Insight 3
Several large-sized CMOs offer services across all scales of operation; most popular packaging formats include tablets / capsules / blisters and vials / cartridges
Sample Insight 4
Interestingly, despite the stringent regulatory standards, a significant proportion of CMOs have procured operational approvals and certifications from the USFDA
Sample Insight 5
The current installed contract manufacturing capacity is over 100 million litres; this capacity is spread across different regions worldwide
Sample Insight 6
Driven by an increasing global demand for small molecule drugs, pharmaceutical contract manufacturing is currently a multi-billion dollar and steadily growing industry
Sample Insight 7
Within APIs, generics will continue to represent the major focus; in the case of FDFs, the future growth is expected to be driven by injectables
Sample Insight 8
A closer look at the market landscape reveals a well distributed opportunity in terms of various primary packaging forms, scale of operations and size of manufacturers
Sample Insight 9
Specifically, CMOs based in Asia Pacific are likely to command an increasing share of the market in the long-term
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com.
The present pipeline of pharmaceutical products is becoming increasingly complex and requires specialized facilities, equipment and operational expertise. In addition, the costs associated with acquiring manufacturing capabilities are exorbitant and, therefore, it is difficult for companies with limited finances and capacity constraints to succeed by themselves. Over the years, the contract manufacturing market has grown into a prominent and promising segment of the overall pharmaceutical industry. In fact, post 2000, more than 150 new CMOs have been established, offering cost-efficient solutions to several stakeholders in the industry.
Sample Insight 1
Discussions with several industry stakeholders not only confirm the present importance of CMOs but also highlight the value likely to be created by them in the long term
Sample Insight 2
The contract services market landscape, featuring the presence of over 500 companies, is highly fragmented; a number of players have both API and FDF manufacturing capability
Sample Insight 3
Several large-sized CMOs offer services across all scales of operation; most popular packaging formats include tablets / capsules / blisters and vials / cartridges
Sample Insight 4
Interestingly, despite the stringent regulatory standards, a significant proportion of CMOs have procured operational approvals and certifications from the USFDA
Sample Insight 5
The current installed contract manufacturing capacity is over 100 million litres; this capacity is spread across different regions worldwide
Sample Insight 6
Driven by an increasing global demand for small molecule drugs, pharmaceutical contract manufacturing is currently a multi-billion dollar and steadily growing industry
Sample Insight 7
Within APIs, generics will continue to represent the major focus; in the case of FDFs, the future growth is expected to be driven by injectables
Sample Insight 8
A closer look at the market landscape reveals a well distributed opportunity in terms of various primary packaging forms, scale of operations and size of manufacturers
Sample Insight 9
Specifically, CMOs based in Asia Pacific are likely to command an increasing share of the market in the long-term
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at sales@rootsanalysis.com. Alternatively, you can place an Order by filling this Order Form.
Roots Analysis – Leaders in Pharmaceutical & Biotechnology Market Research
You may also be interested in the following titles:
- AI-based Drug Discovery Market (2nd Edition)
- CAR-T Cell Therapies: Intellectual Property Landscape
- Plant-based Meats: Intellectual Property Landscape
Our Social Media Platform
Web: https://www.rootsanalysis.com/
Targeted Protein Degradation and the Rise of Kymera Therapeutics
Applications of Blockchain in Various Sectors: An Introduction
Abuse Deterrent Formulation Technologies: Combating Prescription Drug Abuse
About Author
